Financials Scandinavian ChemoTech AB
Equities
CMOTEC B
SE0009242654
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 SEK | +1.31% | +2.65% | -14.07% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Capitalization 1 | 81.91 | 164.1 | 60.67 | 41.08 | 41.08 | - |
Enterprise Value (EV) 1 | 81.91 | 164.1 | 60.67 | 43.97 | 31.28 | 41.08 |
P/E ratio | -5.72 x | - | -2.21 x | -1.73 x | - | - |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 57.4 x | 3,349 x | - | 15.6 x | 5.55 x | 3.16 x |
EV / Revenue | 57.4 x | 3,349 x | - | 15.6 x | 4.23 x | 3.16 x |
EV / EBITDA | - | -11.5 x | - | -2.5 x | -2.67 x | -3.99 x |
EV / FCF | - | - | - | -2.5 x | - | - |
FCF Yield | - | - | - | -39.9% | - | - |
Price to Book | - | 6.86 x | - | - | - | - |
Nbr of stocks (in thousands) | 6,045 | 9,629 | 12,014 | 17,937 | 17,937 | - |
Reference price 2 | 13.55 | 17.04 | 5.050 | 2.290 | 2.290 | 2.290 |
Announcement Date | 08/03/21 | 08/03/22 | 07/03/23 | 05/03/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net sales 1 | 1.427 | 0.049 | - | 2.822 | 7.4 | 13 |
EBITDA 1 | - | -14.26 | - | -17.56 | -11.7 | -10.3 |
EBIT 1 | - | -17.08 | - | -20.24 | -13.7 | -12.3 |
Operating Margin | - | -34,851.02% | - | -717.12% | -185.14% | -94.62% |
Earnings before Tax (EBT) 1 | - | - | - | -21.09 | -15.3 | -12.3 |
Net income 1 | - | - | -22.75 | -21.09 | -15.3 | -12.3 |
Net margin | - | - | - | -747.38% | -206.76% | -94.62% |
EPS 2 | -2.370 | - | -2.280 | -1.560 | - | - |
Free Cash Flow 1 | - | - | - | -18 | - | - |
FCF margin | - | - | - | -529.41% | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 08/03/21 | 08/03/22 | 07/03/23 | 05/03/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 1.181 | 1.08 | 1.382 | 1.7 | 2 | 2.3 | - |
EBITDA 1 | - | -5.245 | -3.319 | -2.296 | -2.8 | -3.3 | -3.2 | - |
EBIT 1 | - | -5.978 | -4.026 | -2.798 | -3.3 | -3.8 | -3.7 | - |
Operating Margin | - | -506.18% | -372.78% | -202.46% | -194.12% | -190% | -160.87% | - |
Earnings before Tax (EBT) | -5.034 | - | - | - | - | - | - | - |
Net income 1 | -5.034 | - | - | - | -3.7 | -4.2 | -4.1 | -3.6 |
Net margin | - | - | - | - | -217.65% | -210% | -178.26% | - |
EPS | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 25/05/23 | 15/08/23 | 17/10/23 | 07/05/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 4 | - | - |
Net Cash position 1 | - | - | - | - | 9.8 | - |
Leverage (Debt/EBITDA) | - | - | - | -0.2564 x | - | - |
Free Cash Flow 1 | - | - | - | -18 | - | - |
ROE (net income / shareholders' equity) | - | -107% | - | -169% | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | 2.480 | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | 3.33 | - | - | - | - |
Capex / Sales | - | 6,795.92% | - | - | - | - |
Announcement Date | 08/03/21 | 08/03/22 | 07/03/23 | 05/03/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.07% | 3.79M | |
+11.73% | 226B | |
+9.53% | 188B | |
+14.63% | 137B | |
+27.47% | 108B | |
+0.53% | 63.19B | |
+13.73% | 52.26B | |
+4.86% | 51B | |
+7.72% | 43.89B | |
+7.86% | 38.07B |
- Stock Market
- Equities
- CMOTEC B Stock
- Financials Scandinavian ChemoTech AB